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Abstract
Background: Several Chlamydia pneumoniae (Cp) biomarkers have been associated with asthma but Cp-specific IgE (Cp IgE)
has not been investigated extensively. Our objective was to investigate Cp IgE in community adult asthma patients.
Methods: (1) Prevalence of Cp IgE (measured by immunoblotting) and Cp DNA (by polymerase chain reaction) in peripheral
blood, and biomarker associations with asthma severity. (2) Case-control studies of Cp IgE association with asthma using
healthy blood donor (study 1) and non-asthmatic clinic patient (study 2) controls.
Results: Of 66 asthma subjects (mean age 40.9 years, range 5–75, 59% male, 45% ever-smokers) 33 (50%) were Cp IgE
positive and 16 (24%) were Cp DNA positive (P=0.001 for association of Cp IgE and DNA). Cp IgE was detected in 21% of
mild intermittent asthma v 79% of severe persistent asthma (test for trend over severity categories, P=0.002). Cp IgE
detection was significantly (P=0.001) associated with asthma when compared to healthy blood donor controls but not
when compared to clinic controls.
Conclusions: Half of this sample of community asthma patients had detectable IgE against C. pneumoniae. Cp IgE was
strongly and positively associated with asthma severity and with asthma when healthy blood donor controls were used.
These results support the inclusion of Cp IgE as a biomarker in future studies of infectious contributions to asthma
pathogenesis.
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Introduction
‘‘Bacterial allergy’’ was once thought to be a mechanism linking
respiratory bacterial infections and asthma symptoms [1].
Currently, viral infections are widely acknowledged as precipitants
of asthma exacerbations, and may be involved in the natural
history of asthma, as reviewed elsewhere [2]. Virus-specific IgE
(e.g. against RSV) is one possible mechanism for the viral
pathogenesis of asthma [3]. In addition to the focus on viral
infections and asthma, an emerging body of evidence suggests that
the atypical bacteria Chlamydia pneumoniae (Cp) and Mycoplasma
pneumoniae (Mp) are associated with asthma [4,5,6], although
whether these associations are causal remains a matter of some
debate. Regarding Cp the preponderance of evidence favors an
association with asthma severity [7]. However, there is also
evidence for associations with asthma inception [8], exacerbation
[9] and lung remodeling [10]. It is currently not established
whether these atypical infections directly create asthma or
secondarily and opportunistically infect previously susceptible
asthmatic lungs [5]. In either case pathogen-specific IgE, were it to
be present, might be expected to augment the severity of asthma.
There have been some reports of asthma associated with specific
IgE against Cp [11,12,13] and against Mp [14,15] but the data are
sparse. In this study we measured the prevalence of Cp-specific
IgE (Cp IgE) in a sample of community adult asthma patients and
investigated associations with disease severity. We also performed
two case-control studies of the association of Cp IgE and asthma
using healthy blood donors and non-asthmatic clinic patients as
controls. Lastly, we report a preliminary exploration of whether
the Cp IgE biomarker would predict treatment outcome in those
subjects who elected empiric azithromycin for their asthma.
Materials and Methods
Ethics statement
The Dean Foundation, Madison, Wisconsin and the University
of Massachusetts, Amherst, Massachusetts human subjects com-
mittees both approved the study. All clinical subjects (asthma cases
and clinic controls) provided written informed consent. The St.
Marys Hospital, Madison human subjects committee reviewed
and approved the use of outdated and to-be-discarded Wisconsin
blood donor samples in a Health Insurance Portability and
Accountability Act (HIPAA) compliant fashion. The University of
Massachusetts, Amherst human subjects committee likewise
approved the use of Massachusetts blood donor samples. In order
to comply with HIPAA standards, none of the blood donor
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35945samples could be linked to individual donors, therefore written
informed consent from individuals was not obtained for these
samples with the approval of the respective committees.
Asthma subjects
One of the investigators (DLH) enrolled a consecutive series of
66 patients with physician-diagnosed asthma encountered in a
community-based non-academic primary care practice. The
subjects were either patients of the practice or were seen in
consultation for their asthma. Asthma severity was recorded
according to current guidelines as either intermittent or persistent
(mild, moderate or severe) [16]. Pulmonary function test
reversibility, either spontaneously or after treatment, was not a
study requirement.
Case-control study design
We performed two case-control studies. In Study 1 (blood donor
controls) we tested blood donor samples for Cp IgE and compared
the results to asthma cases. As controls we tested 25 platelet pheresis
donor samples from Baystate Medical Center, Springfield MA and
26 platelet donors from the Red Cross and St. Marys Hospital,
Madison, Wisconsin. Deidentified demographic data consisting of
gender and age were available for blood donor controls. We did not
test for Cp DNA in blood donor controls because these samples
consisted of plasma/platelets and did not include mononuclear cells
that are expected to carry this intracellular pathogen. In Study 2
(clinic controls), we tested peripheral blood samples for Cp IgE and
DNA from non-asthma outpatients. These control subjects were
without known acute or chronic respiratory illnesses and were
matched to a case patient by gender, smoking status (current, ex-,
never) and age (+/210 years). After a case subject was enrolled, the
investigator (DLH) then identified an appropriate patient who later
attended the practice to be a matched control. After 20 such
controls were enrolled and tested it became obvious that no
significant differences would be found for Cp IgE, therefore
enrollment of further clinic controls was suspended.
Cp-specific IgE
Proteins of purified chlamydial elementary bodies (EBs) from Cp
TW183 were separated on 4–20% NU-PAGE gradient gels and
transferred by Western blot to PVDF membranes. Because of the
low concentration of IgE in patient sera, prior to IgE blotting, sera
were immunoabsorbed in an anti-human gamma-chain specific
protein G agarose system to remove competing IgG as previously
reported [17]. Since protein G does not bind IgE antibodies [18,19]
the resultant supernatant became ‘enriched’ for IgE. The
supernatant was diluted and used to probe the individual blot
strips. Blot strips were then washed and incubated with an AP-
conjugated goat anti-human IgE (e-chain specific) antibody (KPL
Scientific Inc., Gaithersburg, MD). The blots were visualized after
addition of BCIP/NBT alkaline phosphatase substrate solution
(Sigma-Aldrich, St. Louis, MO). The identity of Chlamydia-specific
bands recognized by patient IgE on each blot were determined
based on known molecular weight patterns of the various Chlamydia
surface proteins as previously characterized and confirmed [20,21].
We also performed specific comparative staining with purified
Chlamydia lipopolysaccharide (LPS) and recombinant major outer
membrane protein (MOMP) to confirm identity of these proteins.
Cp-specific DNA
PCR was performed as previously described and reported [22].
Briefly, genomic DNA was isolated from whole blood using the
QIAMP DNA Blood mini kit (Qiagen Inc., Valencia, CA).
Previously published Cp primers (Cpn A and B) were used to
amplify a 463 bp product [23]. The PCR products were separated
by gel electrophoresis on 2% agarose gels and visualized by staining
with ethidium bromide. In order to independently validate the
presence of Cp in our blood samples, we sent blinded samples of
whole blood and extracted DNA to the lab of Dr. Bernhard
Kaltenboeck(AuburnUniversity,AL)whousedthe23SrRNA gene
as target as previously described for qPCR analysis [24].
Azithromycin treatment
Some patients who were enrolled as asthma subjects in this
study elected to receive empiric treatment with azithromycin from
their physician for persistent and/or refractory asthma symptoms.
These subjects were prescribed azithromycin 500 milligrams daily
for 3 days, then 750 milligrams once weekly for an additional 11
weeks and they reported their clinical response at follow up visits
as part of their usual care. A subset of these patients had serial
testing performed for Cp IgE and DNA in peripheral blood.
Statistical methods
We used Fishers Exact test for categorical variables, and t-tests
for continuous variables reported as mean and standard deviation.
P-values less than 0.05 (2-tailed) were considered significant.
Results
We enrolled and tested 66 asthma patients between June 2009
and February 2011. This sample contained a wide range of ages,
asthma severity and age of asthma onset. The majority of subjects
were white, non-Hispanic and never and ex-smokers. Forty eight
percent were encountered in consultation because they had
refractory asthma. Fourteen percent reported a coexisting clinical
diagnosis of COPD. Table 1 presents further details of the subject
characteristics.
Biomarker prevalence
Cp IgE. Cp IgE was detected in 33 (50%) of the 66 asthma
subjects. Figure 1 shows typical western blot strips as well as the
relevant positive and negative controls. The figure clearly
demonstrates that a small number of chlamydial proteins
induced Cp IgE. Five known chlamydial antigens were the most
commonly recognized bands: the cysteine rich protein A (CrpA,
49%), the major outer membrane protein (MOMP, 33%), the
Chlamydia lectin binding proteins (LBP, 18, 27 and 32 KDa, 15%
to 27%), the chlamydial heat shock protein 60 (cHSP60, 18%) and
the chlamydial lipopolysaccharide (cLPS, 18%) (Table 2). These
proteins were identified by molecular weight estimations and
specific comparative staining with purified Chlamydia cLPS and
recombinant MOMP protein as described in Methods.
Cp DNA. Cp DNA was detected in 16 (24%) of 66 asthma
subjects. Figure 2 shows a representative agarose gel of individual
patient sample PCR products at 463 bp. There was a strong and
statistically significant association between being Cp DNA positive
and being Cp IgE positive: 14 (88%) of 16 PCR positive subjects
were also IgE positive (P=0.001). In addition, there was a group
of 19 (38%) of 50 PCR negative subjects who were also IgE
positive, suggesting a previous infection or current persistent
infection without productive progeny that could be released into
the blood stream
A second lab performed qPCR on samples from 52 of our
asthma cases and from 29 other samples in a blinded manner
using different primers. Of the 81 total samples that were tested by
both PCR methods, the second lab confirmed PCR positivity in 16
(62%) of 26 of our Cp DNA positive samples and found PCR
Chlamydia pneumoniae-Specific IgE and Asthma
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(P#0.0001 for overall agreement by Fishers Exact test). Results
were similar when the 52 asthma cases were analyzed separately: 8
(57%) of 14 of our positive samples also tested positive at the
second lab, and 36 (95%) of 38 of our negative samples tested
negative (P#0.0001).
Table 1. Subject characteristics.
Asthma cases (n=66) Blood donor controls (n=51) Clinic controls (n=20)
Mean age (Sd) 40.9 (17.8) 49.2 (12.9) 48.6 (14.7)
Range 5–75 21–79 18–69
Gender, no. (%) male 39 (59) 34 (67) 12 (60)
Smoking, no (%) NA
Current 9 (14) 1 (5)
Ex- 14 (21) 5 (25)
Never 43 (65) 14 (70)
Race, no. (%) NA
White 57 (86) 17 (85)
Black 5 (8) 1 (5)
Asian 4 (6) 2 (10)
Mean age asthma onset (Sd) 22.4 (19.1) - -
,18 yoa, no, (%) 32 (48)
$18 yoa 34 (52)
Asthma severity, no. (%) --
Intermittent 19 (29)
Mild persistent 6 (9)
Moderate persistent 27 (41)
Severe persistent 14 (21)
Coexisitng COPD, no. (%) 10 (15) --
NA=data not available; -=not applicable.
doi:10.1371/journal.pone.0035945.t001
Figure 1. Representative Western blot for the detection of Chlamydia-specific IgE. Whole C. pneumoniae lysate was electrophoresed using
SDS-PAGE and blotted onto PVDF membrane. Each patient’s Cp-specific IgE antibodies were enriched by affinity chromatography and used to probe
each strip. The representative figure shows the presence of Chlamydia-specific IgE antibodies in the serum of patients in samples 1 through 4 and
absence in samples 5 and 6. The lanes labeled + and 2 display the respective controls.
doi:10.1371/journal.pone.0035945.g001
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Cp IgE was detected in 4 (21%) of 19 subjects with mild
intermittent asthma compared to 29 (62%) of 47 with persistent
asthma (P=0.006). There was also a significant (P=0.002) positive
linear association between Cp IgE and GINA severity categories
(Figure 3). Cp DNA was detected in 3 (16%) of 19 patients with
mild intermittent asthma compared to 13 (28%) of 47 with
persistent asthma (P=0.36). There was no significant linear
association between DNA positivity and GINA asthma severity
categories (P=0.56).
Cp IgE association with asthma
Cp IgE was significantly (P,0.0001) more prevalent in the 66
asthma cases (33 of 66) compared to the 51 blood donor controls (4
of 51) (Table 3). Results remained significant when asthma cases
were separately compared to blood donor controls from Wisconsin
(1 of 26 Cp IgE positive, P,0.0001) and from Massachusetts (3 of
25 positive, P=0.001). We found no significant differences in Cp
DNA or Cp IgE prevalence between the matched cases and the
matched clinic controls (Table 3).
Temporal changes in Cp IgE
Nine of 66 asthma subjects had repeat Cp IgE and DNA testing
performed a range of 4 to 16 months after enrolment (Table 4). Cp
IgE was present at enrolment and persisted in 7 of 9 subjects and
was negative at enrolment but was detected later in the other 2
subjects. Since all but one of the 9 subjects described in Table 4
received azithromycin prior to obtaining the follow up sample(s),
azithromycin treatment therefore did not seem to affect detection
of Cp IgE in this small sample. Cp DNA was also detected at
enrolment in 7 of 9 subjects; 5 of 7 DNA positive subjects became
DNA negative after azithromycin treatment. Notably in Case 6,
Cp DNA reappeared in association with a relapse after
azithromycin treatment. Thus, there was some indication that
azithromycin treatment might diminish the ability to detect Cp
DNA in peripheral blood. In Case 3, Cp DNA was not detected at
baseline but was positive after treatment, despite a positive clinical
response to azithromycin. In Case 9, Cp DNA detection became
negative in the absence of treatment despite persistence of
symptoms.
Cp IgE and azithromycin treatment outcome
Thirty-nine asthma patients from the cohort of 66 asthma
subjects elected empiric azithromycin treatment from their
personal physician and reported clinical outcome. We therefore
performed an unplanned exploratory analysis of baseline Cp
biomarkers and treatment outcome. Twenty-one (81%) of 26
subjects whose baseline (pre-treatment) Cp IgE was positive
reported improvement compared to 12 (92%) of 13 who were Cp
IgE negative at baseline (P=0.64). Ten (71%) of 14 patients whose
baseline Cp DNA test was positive reported clinical improvement
versus 23 (92%) of 25 Cp DNA negative subjects (P=0.16). Thus,
neither pretreatment Cp IgE nor pretreatment Cp DNA was
significantly associated with a clinical report of improvement after
azithromycin treatment in these analyses.
Discussion
We report results from asthma patients drawn from a
community practice. To increase generalizability, this sample
purposely included covariates such as smoking, coexisting COPD
and a broad range of clinical severity. These covariates are often
limited or used as exclusion criteria in asthma research [25,26].
Significant exclusions may produce precise, but not very
generalizable results. Because of our relatively small sample size,
we were unable to perform meaningful subgroup analyses on
smoking or on co morbid COPD. Such analyses will be important
in future, larger studies because there is a growing recognition that
asthma and COPD may not be entirely unrelated diseases [27]. In
particular, the ‘‘overlap syndrome’’ (patients manifesting both
asthma and COPD characteristics) appears to comprise half or
more of older adults with obstructive airways disease [28]. We
limited our analysis to associations with disease severity for which
we had adequate power.
We detected Cp IgE in a large proportion (50%) of asthma
patients from a community practice and found that Cp IgE had a
positive ‘‘dose response’’ relationship with asthma severity. We
Table 2. Cp-specific IgE band frequencies*.
Protein
{ Frequency, n (%)
6 kDa LPS 6 (18)
15 kDa CrpA 16 (49)
18 kDa LBP 5 (15)
27 kDa LBP 5 (15)
32 kDa LBP 9 (27)
37 kDa SapA 2 (6)
40 kDa MOMP 11 (33)
43 kDa CHLPS 5 (15)
52–55 kDa Unknown 5 (15)
60 kDa HSP60 6 (18)
64–68 kDa Unknown 5 (15)
70 kDa HSP70 2 (6)
99 kDa Omp4 1 (3)
*=Among 33 IgE positive cases.
{=In ascending order of molecular weight.
doi:10.1371/journal.pone.0035945.t002
Figure 2. Representative PCR data. PCR products were separated on agarose gel and stained with ethidium bromide to display amplified
products. The figure shows the base pair ladder (L), positive control (P), negative control (N) and representative samples with/without positive bands.
Samples 3, 5–7, 9, 11, 14 and 17 are positive while the others did not display the positive band.
doi:10.1371/journal.pone.0035945.g002
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diagnosis using healthy blood donors as controls. These two
findings (disease association and ‘‘dose response’’) are two
epidemiological criteria that support (but cannot in themselves
prove) a causal association. Early observations led clinicians to
speculate that infections, via bacterial allergy, played an important
role in asthma pathogenesis [1]. Subsequent epidemiological
evidence indicated that asthma was almost always associated with
elevated IgE levels that were not necessarily induced by common
aeroallergens [29]. This observation led the investigators to suggest
that IgE associated with asthma could be related to ‘‘missing
antigens.’’ Our current findings and the research of others suggest
that microbial infection could be an additional source for antigenic
stimulation of IgE in asthma. This evidence has accumulated from
studies showing the presence of virus- [30], Mycoplasma- [15] and
Chlamydia-specific [11,12,13] IgE in asthma but the data are
sparse. In the current study we provide further evidence that
chlamydial biomarkers (Cp-specific IgE and Cp DNA) are
commonly detected in outpatients with physician-diagnosed
asthma.
Although C. pneumoniae has approximately 1000 coding genes,
only a small number of antigens appeared to induce IgE
production in this sample of asthmatic patients. The most
commonly recognized bands of known function in our Western
blot assays (CrpA, MOMP, LBPs, HSP60 and LPS) are located on
the outer surface of elementary bodies and/or are secreted by the
organism during acute or persistent infection. The outer
membrane proteins (MOMP and CrpA) are expressed on the
infectious elementary body (EB) and are therefore logical
candidates as antigens to stimulate humoral immunity during
the infectious phase. HSP60 is up regulated and secreted during
persistent intracellular infection, and may contribute to the
pathogenesis of chronic inflammatory chlamydial diseases [31].
The chlamydial LPS has been associated with acute coronary
artery disease but a role in asthma has not been investigated [32].
In addition to these reasonably well characterized chlamydial
Figure 3. Prevalence of Cp biomarkers (IgE and DNA) according to asthma severity category. Y-axis=Percent of group testing positive.
*P=0.002 compared to control; **P=,0.0001 compared to control; P=0.002 for linear trend in Cp IgE for asthma severity categories; P=0.27 for
linear trend in Cp DNA. Blood donor controls were not tested for Cp DNA.
doi:10.1371/journal.pone.0035945.g003
Table 3. Case-Control results.
Study 1 Study 2
All asthma cases
Blood donor
controls P-value*
Matched asthma
cases
Matched clinic
controls P-value*
No. 66 51 20 20
Cp IgE, no. (%)
positive 33 (50) 4 (8) ,0.0001 11 (55) 15 (75) 0.320
negative 33 (50) 47 (92) 9 (45) 5 (25)
Cp DNA, no. (%)
positive 16 (24) NA - 8 (40) 7 (35) 1.000
negative 50 (76) NA 12 (60) 13 (65)
*Fishers Exact test; NA=data not available; -=not applicable.
doi:10.1371/journal.pone.0035945.t003
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against two sets of chlamydial antigens of unknown function (52–
55 kDa and 64–68 kDa).
We detected Cp DNA in half of subjects who were Cp IgE
positive. It is possible that the remainder of Cp IgE positive, DNA
negative subjects were persistently sensitized but no longer
infected. Alternatively, the Cp IgE positive, DNA negative subjects
might have been persistently infected but were not bacteremic at
the time of sampling. Our data cannot distinguish between these
possibilities. The statistically significant (P,0.01) association
between Cp DNA positivity and Cp IgE positivity in peripheral
blood supports the conclusion that antigenic stimulation by an
active C. pneumoniae infection could be responsible for the presence
of circulating Cp-specific IgE. Our results cannot determine
whether the lung, as we suspect, was the source of the active
infection. Detection of Cp DNA in peripheral blood has correlated
with Cp DNA detection in BAL and bronchial biopsy specimens
from subjects with COPD [33]. Our data are consistent with the
possibility that a similar process occurs in asthma. Further research
will be required to establish whether an active lung infection is
responsible for triggering Cp IgE production in asthma, and to
what extent seeding of the bloodstream from the lung can occur.
IgE positivity against one or more Cp protein antigens was
significantly (P,0.001) associated with asthma severity by several
criteria (Figure 3). As mentioned previously, this ‘‘dose-response’’
association is one epidemiological criterion supporting a causal
association. Cp DNA was also more prevalent in severe persistent
(36%) than in mild intermittent (16%) asthma but this difference
was not statistically significant. One possible interpretation of these
results is that a specific host response to C. pneumoniae, rather than
mere presence of the organism, is required for disease expression.
In addition to an association with asthma severity, Cp IgE was
also significantly (P,0.0001) associated with asthma, using blood
donors as controls (Table 3). Asthma case and clinic control
samples were refrigerated and shipped on ice within several days
to the testing laboratory. Blood donor control samples were
refrigerated until they became outdated and then shipped, raising
the issue whether prolonged storage was associated with
degradation of IgE resulting in lack of detection. We do not
believe this is likely, however, as immunoglobulins are very stable
protein molecules and refrigeration should prevent bacterial
enzyme degradation or cellular uptake and processing of these
Igs over this relatively short period of time [34,35]. Somewhat
surprisingly, no association of Cp IgE and asthma was found when
Table 4. Patients with multiple specimens.
Age and gender Specimen # Date Cp DNA Cp IgE Azithromycin treatment?
1) 25 M 001 6/17/09 + 2 yes
049 2/17/10 2 +
2) 15 F 023 11/25/09 ++ yes
056 3/2/10 2 +
3) 48 M 021 11/11/09 2 + yes
063 3/12/10 ++
4) 66 F 020 11/11/09 ++ yes
065 3/22/10 ++
5) 54 M 018 10/28/09 ++ yes
068 3/30/10 ++
099 1/28/11 2 +
6) 43 M 015 10/21/09 ++ yes
073 4/23/10 2 +
088 10/25/10 ++
7) 38 M 083 8/2/10 22 yes
094 12/17/10 2 +
8) 44 M 052 2/24/10 ++ yes
100 2/1/11 2 +
9) 26 M 019 10/28/09 ++ no
103 2/10/11 2 + yes
+=detected; 2=not detected.
doi:10.1371/journal.pone.0035945.t004
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clinic controls may not be representative of the general population.
The higher prevalence of Cp biomarkers in non-asthma clinic
controls compared to healthy blood donor controls may reflect
differences in exposure to Cp infection between adults in the
general population (as reflected by healthy blood donors) and in a
more selected group that seeks medical care (the clinic controls).
Cp IgE prevalence in clinic controls is consistent with previous
data on allergen-specific IgE, in which non-allergic control groups
may demonstrate differing degrees of IgE positivity [36]. The
presence of specific IgE in clinic controls may indicate that other
permissive factors are also required for disease expression.
Emre et al. [11] performed the only previous case-control study
of the association of asthma and Cp IgE detected by immuno-
blotting. They compared 14 Cp culture positive children with
asthma exacerbations (cases) with 3 control groups (11 Cp culture
positive non-wheezing children with community acquired pneu-
monia, 11 culture negative pediatric asthmatics and 9 culture-
negative asymptomatic pediatric non-asthmatics) and reported
that 12 (86%) cases were Cp IgE positive compared to 9–22% of
the control groups (P,0.01 for each case-control comparison).
The most commonly recognized proteins were at 98 (82%), 78
(60%), 58–60 (71%) and 36 kDa (65%). The only commonly
recognized band found in both the Emre et al. [11] study and ours
was the putative chlamydial heat shock protein (HSP60, 58–
60 kDa) band. Cp HSP60 secretion from infected cells can create
an inflammatory response via activation of toll like receptors [37]
and seroreactivity against Cp HSP60 has been associated with
asthma and with airflow limitation in a previous study [38]. Both
the Emre et al. [11] study and our study support a possible role for
Cp IgE in asthma, and further suggest that chlamydial HSP60
should be examined further for a possible role in asthma
pathogenesis.
Experimental evidence supports the possibility that the
associations of Cp IgE and asthma are causal. Chlamydia-specific
IgE production, with subsequent fixation of the IgE to FceRI
receptors on mast cells and basophils, could lead to the initiation
and propagation of immediate and sustained IgE-mediated
inflammation for the duration of the bacterial presence [39].
One characteristic of atypical lung infection in human asthma is
the presence of increased mast cell numbers [40]. Further research
is required to determine whether these infection-associated mast
cells are activated by Cp IgE to produce worsening asthma
symptoms. In addition, chamydial infection of dendritic lung cells
has been shown to promote overall Th2 immunity and airways
hyperreactivity [41], suggesting the possibility that infection might
also promote a more general atopic predisposition. Recent
experimental evidence indicates that chlamydial lung infection
may induce or worsen several hallmarks of asthma including
airway inflammation [42,43,44], airway hyperresponsiveness
[42,45], mucous hypersecretion [45,46] and IL-13 production
[45]. IL-13 can in turn promote susceptibility to chlamydial lung
infection [47] that could in theory produce a positive feedback
loop to create or worsen asthma. To this end, it is noteworthy most
antigens that induce the secretion of IL-13 also stimulate IL-4 and
IL-5 production. Both of these cytokines are highly pleiotrophic
with multiple regulatory functions beyond IgE regulation,
including an important role in modulation of macrophage activity
[48]. Effects of chlamydial infection have been demonstrated in
both atopic [44,49] and non-atopic [50] animal models, and
include augmented neutrophilic inflammation and Th1/Th17
effects [51]. The effects are also dependent on the timing
[43,44,45] and the dose [44] of infection. Taken together, these
experimental results coupled with the clinical observations support
the possibility that human chlamydial lung infection can result in
pathogen-specific IgE production that could worsen asthma, as
suggested by our results. However, other mechanisms not
involving IgE have also been demonstrated. These types of
experimental studies may serve as platforms for elucidation of
further explanatory mechanisms regarding a potential role for
both pathogen-specific IgE and for other infection-related
mechanisms in asthma pathogenesis.
Follow up sampling from a limited number of our subjects
demonstrated clearance of Cp DNA from the circulation in 5 of 7
after treatment with azithromycin, and one of these patients had a
recurrence of Cp DNA detection in the peripheral blood in
association with an asthma relapse later. Due to an unplanned
high frequency of patients electing empiric azithromycin treatment
for their asthma, we took the opportunity to collect data on clinical
response. These reports should be interpreted cautiously because
they were based solely on clinical self-reports from self-selected
subjects and the treatment was not blinded nor randomized. The
majority of asthma patients who elected empiric azithromycin
treatment for their refractory asthma reported that they
experienced significant clinical improvements that were sustained
after treatment was completed. These self-reports are consistent
with previous data of persisting improvements in asthma
symptoms after limited courses of azithromycin treatment
[52,53]. Further evidence is available from a randomized trial
by Simpson et al. [54] who reported that the macrolide
clarithromycin decreased airway IL-8 and neutrophilia, and
improved wheezing and asthma quality of life in subjects with
severe, refractory asthma who were randomized to clarithromycin.
To illustrate the importance of exploring whether biomarkers
can predict treatment response in this context, we performed an
unplanned exploratory analysis to test whether baseline Cp IgE
was associated with patient self-reports of positive outcomes after
taking azithromycin. In a previous randomized, placebo controlled
trial of azithromycin in persistent adult asthma [53], Cp IgA
antibodies were significantly associated with the severity of
subsequent asthma symptoms. High IgA subjects compared to
low IgA subjects were twice as likely to have a positive response to
azithromycin, but the difference was not statistically significant,
perhaps due to insufficient power. In the present study we also
found no statistically significant association between baseline Cp
IgE and self-reported outcome of azithromycin treatment, as over
80% of treated patients reported improvement irrespective of IgE
status. These results cannot be considered conclusive because of
the methodology employed, as discussed above. Nevertheless, it is
worthwhile discussing these preliminary results. Assuming an
actual treatment effect, the lack of predictive power for Cp IgE in
our study may be explained in several ways. First, it is possible that
any treatment effect was due to non-antimicrobial (anti-inflam-
matory or immunomodulatory) mechanisms [55] or to antimicro-
bial activity against other organisms [56]. Another possibility is
that Cp IgE may be only one of many potential microbial
mechanisms involved in ‘‘chlamydial’’ asthma pathogenesis. For
example, C. pneumoniae infection of bronchial epithelial cells can
release histamine in a non-allergic manner via induction of
histamine decarboxylase [57]. Evidence for other potential non-
allergic mechanisms of action include, but may not be limited to,
generation of cytokines such as TNF-alpha, IL-8 and reactive
oxygen species [58], effects on lung dendritic cells [44] and IL-17
[59,60], immunopathologic actions of C. pneumoniae-specific heat
shock protein 60 [38], infection-induced bronchial ciliary
dysfunction [61], bronchial epithelial damage [62] and other
effects on lung structure [45].
Chlamydia pneumoniae-Specific IgE and Asthma
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35945In summary, Chlamydia pneumoniae-specific IgE was commonly
detected by immunoblotting in a consecutive series of outpatients
with asthma, and was significantly and positively associated with
worse disease severity and with asthma using healthy blood donors
as controls. These results are compatible with the concept that
organism-specific IgE generated and sustained by C. pneumoniae
chronic infection may be one of several mechanisms that
contribute to asthma pathogenesis. Our results support the
inclusion of Cp IgE as a biomarker in future studies investigating
a potential role for microbial infection in asthma.
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